Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline (Q36312068)

13 August 2017

1 reference

title

Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline (English)

1 reference

13 August 2017

1 reference

Felmingham D

1

1 reference

13 August 2017

publication date

1 August 2005

1 reference

13 August 2017

published in

Journal of Chemotherapy

1 reference

13 August 2017

volume

17 Suppl 1

1 reference

13 August 2017

page(s)

5-11

1 reference

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Evolution and spread of tetracycline resistance determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Glycylcyclines: third-generation tetracycline antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro activities of two glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro activities of two glycylcyclines against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

In vitro activities of tigecycline against clinical isolates from Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

Tigecycline: a first in class glycylcycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2005.17.SUPPLEMENT-1.5

10.1179/JOC.2005.17.SUPPLEMENT-1.5

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference